(Hacettepe Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Ankara, Türkiye)
Gökçen ÖRGÜL
(Hacettepe Üniversitesi, Tıp Fakültesi, Perinatoloji Bilim Dalı, Kadın Hastalıkları ve Doğum Anabilim Dalı, Ankara, Türkiye)
Nurhayat HALİS
(Hacettepe Üniversitesi, Tıp Fakültesi, Perinatoloji Bilim Dalı, Kadın Hastalıkları ve Doğum Anabilim Dalı, Ankara, Türkiye)
Şehnaz ALP
(Hacettepe Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Ankara, Türkiye)
(Hacettepe Üniversitesi, Tıp Fakültesi, Çocuk Enfeksiyon Hastalıkları Anabilim Dalı, Ankara, Türkiye)
(Hacettepe Üniversitesi, Tıp Fakültesi, Perinatoloji Bilim Dalı, Kadın Hastalıkları ve Doğum Anabilim Dalı, Ankara, Türkiye)
(Hacettepe Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Serhat ÜNAL
(Hacettepe Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Ankara, Türkiye)
Mehmet Sinan BEKSAÇ
(Hacettepe Üniversitesi, Tıp Fakültesi, Perinatoloji Bilim Dalı, Kadın Hastalıkları ve Doğum Anabilim Dalı, Ankara, Türkiye)
Yıl: 2020Cilt: 21Sayı: 3ISSN: 1309-0399 / 1309-0380Sayfa Aralığı: 180 - 186İngilizce

128 0
Perinatal outcomes of twenty-five human immunodeficiency virus-infected pregnant women: Hacettepe University experience
Objective: To evaluate perinatal outcomes in human immunodeficiency virus (HIV) infected pregnant women in Turkey.Material and Methods: Maternal characteristics, pregnancy complications, laboratory findings including HIV load, CD4 cell count, CD4/CD8ratio, neonatal features and final HIV status of the baby were retrospectively analyzed.Results: The sample included 26 singleton pregnancies, from 25 HIV-infected women. The ethnicities were Turkish (n=18), East European(n=4), Asian (n=2) and African (n=2). The majority (76.9%) was aware of their HIV status before becoming pregnant. Four cases (15.3%) werediagnosed during pregnancy and two (7.8%) at the onset of labor. The results for median HIV viral load, CD4 count, and CD4/CD8 ratio at birthwere 20 copies/mL (0-34 587), 577/mm3 (115-977), and 0.7 (0.1-1.9), respectively. The HIV viral load rate was 5.5% in eighteen women takinganti-retroviral treatment. The rates of gestational diabetes mellitus, gestational hypertension, intrauterine growth restriction, and preterm deliverywere 3.8%, 3.8%, 7.6%, and 8% (numbers are 1;1;2;2), respectively. The mean gestational week at birth was 38 weeks and mean birthweight is2972±329 g. Two babies were congenitally infected with HIV (infection rate of 8.3%). There was one needle-related accident during surgery.Conclusion: Timely diagnosis of HIV infection during pregnancy is important for preventing mother to child transmission. HIV infected womenmay give birth to HIV negative babies with the help of a multidisciplinary team, composed of perinatology, infectious diseases, and pediatricsspecialists. (J Turk Ger Gynecol Assoc 2020; 21: 180-6)
DergiAraştırma MakalesiErişime Açık
  • 1. Sheet UGSF. UNAIDS [online] http://www. unaids. org/sites/default/ files/media_asset. UNAIDS_FactSheet_en pdf. 2016.
  • 2. Whitmore SK, Zhang X, Taylor AW, Blair JM. Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr 2011; 57: 218- 22.
  • 3. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, 2018.
  • 4. Ozdemir B, Yetkin MA, Bastug A, But A, Aslaner H, Akinci E, et al. Evaluation of epidemiological, clinical, and laboratory features and mortality of 144 HIV/AIDS cases in Turkey. HIV Clin Trials 2018; 19: 69-74.
  • 5. Tümer A, Serhat Ü. HIV/AIDS epidemiyolojisi ve korunma. Sosyal Politika Çalışmaları Dergisi 2001:4.
  • 6. Çerci P, İnkaya AÇ, Alp Ş, Tümer A, Ünal S. Evaluation of 255 HIV/ AIDS cases: Hacettepe cohort, Ankara, Turkey. Mikrobiyol Bul 2016; 50: 94-103.
  • 7. Centers for Disease Control (CDC). Unexplained immunodeficiency and opportunistic infections in infants--New York, New Jersey, California. MMWR Morb Mortal Wkly Rep 1982; 31: 665-7.
  • 8. Raffe SF, Savage C, Perry LA, Patel A, Keith T, Howell R, et al. The management of HIV in pregnancy: A 10-year experience. Eur J Obstet Gynecol Reprod Biol 2017; 210: 310-3.
  • 9. Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, et al. Earlier initiation of ART and further decline in motherto- child HIV transmission rates, 2000-2011. AIDS 2014; 28: 1049-57.
  • 10. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80.
  • 11. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484-94.
  • 12. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 2009; 23: 519-24.
  • 13. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334: 1617-23.
  • 14. European Mode of Delivery Collaboration. Elective caesareansection versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 1035-9.
  • 15. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22: 973-81.
  • 16. Bakanlığı TCS. HIV/AIDS Tanı ve Tedavi Rehberi; 2019: 181-9.
  • 17. Salters K, Loutfy M, de Pokomandy A, Money D, Pick N, Wang L, et al. Pregnancy incidence and intention after HIV diagnosis among women living with HIV in Canada. PloS One 2017; 12: e0180524.
  • 18. Gipson JD, Koenig MA, Hindin MJ. The effects of unintended pregnancy on infant, child, and parental health: a review of the literature. Stud Fam Plann 2008; 39: 18-38.
  • 19. Wilcher R, Cates W. Reproductive choices for women with HIV. Bull World Health Organ 2009; 87: 833-9.
  • 20. Semprini AE, Fiore S. HIV and pregnancy: is the outlook for mother and baby transformed? Curr Opin Obstet Gynecol 2004; 16: 471-5.
  • 21. TC Sağlık Bakanlığı THSKMoHoT, Turkish Public Health Instutition, Department of Women's Reproductive Health. Doğum Öncesi Bakım Yönetim Rehberi (Antenatal Care Management Guideline). In: Başkanlığı THSKKvÜSD, editor. Ankara: Sağlık Bakanlığı; 2018.
  • 22. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22: 289-99.
  • 23. McCormack SA, Best BM. Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet 2014; 53: 989-1004.
  • 24. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21: 607-15.
  • 25. Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med 2019; 381: 827-40.
  • 26. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018; 379: 979-81.
  • 27. Pope Jr R, Kashuba A. Darunavir for use in pregnant women with HIV. Expert Rev Clin Pharmacol 2017; 10: 1317-27.
  • 28. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol 2008; 66: 179-95.
  • 29. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 2007; 21: 643-5.
  • 30. Boyajian T, Shah PS, Murphy KE. Risk of preeclampsia in HIVpositive pregnant women receiving HAART: a matched cohort study. J Obstet Gynaecol Can 2012; 34: 136-41.
  • 31. Xiao PL, Zhou YB, Chen Y, Yang MX, Song XX, Shi Y, et al. Association between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies. BMC Pregnancy Childbirth 2015; 15: 246.
  • 32. Aho I, Kaijomaa M, Kivelä P, Surcel HM, Sutinen J, Heikinheimo O, et al. Most women living with HIV can deliver vaginally-National data from Finland 1993-2013. PloS One 2018; 13: e0194370.
  • 33. Yudin MH, Caprara D, MacGillivray SJ, Urquia M, Shah RR. A tenyear review of antenatal complications and pregnancy outcomes among HIV-positive pregnant women. J Obstet Gynaecol Can 2016; 38: 35-40.
  • 34. Hall D, Gebhardt S, Theron G, Grové D. Pre-eclampsia and gestational hypertension are less common in HIV infected women. Pregnancy Hypertens 2014; 4: 91-6.
  • 35. Arab K, Spence AR, Czuzoj-Shulman N, Abenhaim HA. Pregnancy outcomes in HIV-positive women: a retrospective cohort study. Arch Gynecol Obstet 2017; 295: 599-606.
  • 36. Moore R, Adler H, Jackson V, Lawless M, Byrne M, Eogan M, et al. Impaired glucose metabolism in HIV-infected pregnant women: a retrospective analysis. Int J STD AIDS 2016; 27: 581-5.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.